GlassScriptPhysician profile
James D Bowen
NPI 1124072434
$378,979.85
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148K · 2020: $79K · 2021: $29K · 2022: $90K · 2023: $25K · 2024: $8,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Consulting Fee: $4,903 · Travel and Lodging: $2,675 · Grant: $2,500 · Food and Beverage: $1,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,062.00 |
| Consulting Fee | $4,903.00 |
| Travel and Lodging | $2,674.69 |
| Grant | $2,500.00 |
| Food and Beverage | $1,724.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $158,075.12 | 2019-2024 | Vumerity |
| Genentech USA, INC. | $52,473.56 | 2019-2023 | Ocrevus |
| Celgene Corporation | $49,577.53 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $48,780.89 | 2021-2023 | Zeposia |
| Novartis Pharmaceuticals Corporation | $46,932.23 | 2019-2024 | Kesimpta |
| Emd Serono, INC. | $8,286.07 | 2019-2023 | |
| Novartis Pharma Ag | $7,448.00 | 2019-2021 | |
| Tg Therapeutics, INC. | $2,215.58 | 2021-2024 | |
| Genzyme Corporation | $2,000.00 | 2022 | |
| Genentech, INC. | $1,688.88 | 2019 | |
| Ani Pharmaceuticals, INC. | $1,400.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $101.99 | 2023 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bowen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.